Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 12 p.m. EDT.
The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at . A replay of the webcast will be available on Praxis’ website for 30 days following the event.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit and follow us on , and .
Investor Contact: Praxis Precision Medicines 857-702-9452 Media Contact: Ian Stone Canale Communications 619-849-5388
